Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

  • Register
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.


Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Preparing word cloud



Type in a keyword to search

Filter by last modified time
See new records

Current Facets and Filters

  • Keywords:clinical (facet)
  • Resource Type:narrative resource (facet)
  • Website Status : Ascending


Sort alphabetically | Sort by count

Recent searches

SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.

(last updated: Oct 12, 2019)

Physical Resource or Software Tool Software

65 Results - per page

Resource NameResource TypeDescriptionKeywordsResource IDProper CitationParent OrganizationRelated ConditionFunding AgencyRelationReferenceWebsite StatusAlternate IDsAlternate URLsOld URLs
CAMDResource, organization portal, consortium, standard specification, narrative resource, portal, data or information resourceA consortium developing new technologies and methods to accelerate the development and review of medical products for neurodegenerative diseases. It is focused on accelerating drug development for patients with chronic neurodegenerative disease, namely, Alzheimer's disease (AD) and Parkinson's disease (PD), by advancing drug development tools for evaluating drug efficacy, conducting clinical trials, and streamlining the process of regulatory review. The consortium focuses on sharing precompetitive patient-level data from the control arms of legacy clinical trials, developing new tools to be submitted to the regulatory agencies, and developing consensus data standards. CAMD has the following areas of focus: (1) qualification of biomarkers, (2) development of common data standards, (3) creation of integrated databases for clinical trials data, and (4) development of quantitative model-based tools for drug development. Regulatory milestones include a qualification opinion with EMA for the use of low baseline hippocampal volume for patient enrichment in pre-dementia trials, and most recently, positive regulatory decisions from the FDA and EMA for the use of a clinical trial simulation tool to aid in trials for mild to moderate stages of set, clinical trial, mild cognitive impairment, clinical, biomarker, metadata standard, disease progression model, consortium, drug, data sharing, disease modeling, drug development, disease model, imaging, cerebral spinal fluidSCR_001389(CAMD, RRID:SCR_001389)Critical Path Institute; Arizona; USA Publicly fundedlisted by: Consortia-pediaLast checked downnlx_152563
Standardization of C-peptide measurements Resource, narrative resource, resource, standard specification, data or information resourceStandardization of c-peptide by calibrating C-peptide measurement to a reference method can increase comparability between laboratories. The C-peptide standardization program is supported to establish reliability in results and facilitate the conduct of international clinical trials. For c-peptide, purified or processed material shows significant matrix effects and cannot be used for calibration. The C-peptide program has evaluated the use of single donor and pooled specimens for use by manufacturers in the calibration of these assays and determined that this strategy will reduce C-peptide variability among different assay methods. The standardization process through manufacturer re-calibration is ongoing.c-peptide, insulin secretion, clinical, calibrationSCR_001499( Standardization of C-peptide measurements , RRID:SCR_001499)University of Missouri School of Medicine; Missouri; USA DiabetesNIDDKlisted by: NIDDK Information Network, submitted by: NIDDK Information NetworkPMID:18420730Last checked downnlx_152766
Parkinson’s Disease Biomarkers Program Data Management Resource (PDBP DMR)Resource, disease-related portal, topical portal, database, standard specification, narrative resource, service resource, portal, storage service resource, data repository, data or information resourceCommon data management resource and web portal to promote discovery of Parkinson's Disease diagnostic and progression biomarker candidates for early detection and measurement of disease progression. PDBP will serve as multi-faceted platform for integrating existing biomarker efforts, standardizing data collection and management across these efforts, accelerating discovery of new biomarkers, and fostering and expanding collaborative opportunities for all stakeholders.parkinson's, clinical neuroinformatics, magnetic resonance, diagnostic, progression, biomarker, clinicalSCR_002517(Parkinson’s Disease Biomarkers Program Data Management Resource (PDBP DMR), RRID:SCR_002517)National Institute of Neurological Disorders and Stroke Parkinson's diseaseNINDS, nlmrelated to: NINDS Repository, MIPAV: Medical Image Processing and Visualization, recommended by: National Library of Medicine, BRAIN Initiative, listed by: NeuroImaging Tools and Resources Collaboratory (NITRC)Last checked downnlx_155919
NIH MRI Study of Normal Brain DevelopmentResource, data set, narrative resource, experimental protocol, data or information resourceData sets of clinical / behavioral and image data are available for download by qualified researchers from a seven year, multi-site, longitudinal study using magnetic resonance technologies to study brain maturation in healthy, typically-developing infants, children, and adolescents and to correlate brain development with cognitive and behavioral development. The information obtained in this study is expected to provide essential data for understanding the course of normal brain development as a basis for understanding atypical brain development associated with a variety of developmental, neurological, and neuropsychiatric disorders affecting children and adults. This study enrolled over 500 children, ranging from infancy to young adulthood. The goal was to study each participant at least three times over the course of the project at one of six Pediatric Centers across the United States. Brain MR and clinical/behavioral data have been compiled and analyzed at a Data Coordinating Center and Clinical Coordinating Center. Additionally, MR spectroscopy and DTI data are being analyzed. The study was organized around two objectives corresponding to two age ranges at the time of enrollment, each with its own protocols. * Objective 1 enrolled children ages 4 years, 6 months through 18 years (total N = 433). This sample was recruited across the six Pediatric Study Centers using community based sampling to reflect the demographics of the United States in terms of income, race, and ethnicity. The subjects were studied with both imaging and clinical/behavioral measures at two year intervals for three time points. * Objective 2 enrolled newborns, infants, toddlers, and preschoolers from birth through 4 years, 5 months, who were studied three or more times at two Pediatric Study Centers at intervals ranging from three months for the youngest subjects to one year as the children approach the Objective 1 age range. Both imaging and clinical/behavioral measures were collected at each time point. Participant recruitment used community based sampling that included hospital venues (e.g., maternity wards and nurseries, satellite physician offices, and well-child clinics), community organizations (e.g., day-care centers, schools, and churches), and siblings of children participating in other research at the Pediatric Study Centers. At timepoint 1, of those enrolled, 114 children had T1 scans that passed quality control checks. Staged data release plan: The first data release included structural MR images and clinical/behavioral data from the first assessments, Visit 1, for Objective 1. A second data release included structural MRI and clinical/behavioral data from the second visit for Objective 1. A third data release included structural MRI data for both Objective 1 and 2 and all time points, as well as preliminary spectroscopy data. A fourth data release added cortical thickness, gyrification and cortical surface data. Yet to be released are longitudinally registered anatomic MRI data and diffusion tensor data. A collaborative effort among the participating centers and NIH resulted in age-appropriate MR protocols and clinical/behavioral batteries of instruments. A summary of this protocol is available as a Protocol release document. Details of the project, such as study design, rationale, recruitment, instrument battery, MRI acquisition details, and quality controls can be found in the study protocol. Also available are the MRI procedure manual and Clinical/Behavioral procedure manuals for Objective 1 and Objective 2.young human, child, pediatric, experimental protocol, brain, brain development, development, mri, minc, clinical, behavior, anatomical mri, diffusion tensor imaging, mr spectroscopy, adolescent, clinical data, behavioral data, data visualization software, clinical measure, behavioral measure, physical neurological examination, behavioral rating, neuropsychological testing, structured psychiatric interview, hormonal measure, image collection, neonate, clinical neuroinformatics, dicom, minc2, magnetic resonance, niftiSCR_003394(NIH MRI Study of Normal Brain Development, RRID:SCR_003394)National Institutes of Health Healthy, NormalNICHD, NIDA, NIH Blueprint for Neuroscience Research, NIMH, NINDSrelated to: NIH Data Sharing Repositories, listed by: NeuroImaging Tools and Resources Collaboratory (NITRC), Biositemaps, NIH Data Sharing RepositoriesLast checked downnif-0000-00201,
TRANSFoRm Clinical Research Information ModelResource, narrative resource, report, standard specification, data or information resourceA clinical research information model for the integration of clinical research covering randomized clinical trials (RCT), case-control studies and database searches into the TRANSFoRm application development. TRANSFoRm clinical research is based on primary care data, clinical data and genetic data stored in databases and electronic health records and employs the principle of reusing primary care data, adapting data collection by patient reported outcomes (PRO) and eSource based Case Report Forms. CRIM was developed using the TRANSFoRm clinical use cases of GORD and Diabetes. Their use case driven approach consisted of three levels of modelling drawing heavily on the clinical research workflow of the use cases. Different available information models were evaluated for their usefulness to represent TRANSFoRm clinical research, including for example CTOM of caBIG, Primary Care Research Object Model (PRCOM) of ePCRN and BRIDG of CDISC. The PCROM model turned out to be the most suitable and it was possible to extend and modify this model with only 12 new information objects, 3 episode of care related objects and 2 areas to satisfy all requirements of the TRANSFoRm research use cases. Now the information model covers Good Clinical Practice (GCP) compliant research, as well as case control studies and database search studies, including the interaction between patient and GP (family doctor) during patient consultation, appointment, screening, patient recruitment and adverse event reporting.clinical, randomized clinical trial, clinical trial, primary care, genetic, clinical research, electronic health record, model, interoperabilitySCR_003889(TRANSFoRm Clinical Research Information Model, RRID:SCR_003889)TRANSFoRm used by: TRANSFoRm Data Integration Models, uses: Clinical Data Interchange Standards ConsortiumLast checked downnlx_158219
BioSHaREResource, organization portal, consortium, standard specification, narrative resource, portal, data or information resourceA consortium of leading biobanks and international researchers from all domains of biobanking science to ensure the development of harmonized measures and standardized computing infrastructures enabling the effective pooling of data and key measures of life-style, social circumstances and environment, as well as critical sub-components of the phenotypes associated with common complex diseases. The overall aim is to build upon tools and methods available to achieve solutions for researchers to use pooled data from different cohort and biobank studies. This, in order to obtain the very large sample sizes needed to investigate current questions in multifactorial diseases, notably on gene-environment interactions. This aim will be achieved through the development of harmonization and standardization tools, implementation of these tools and demonstration of their applicability. BioSHaRE researchers are collaborating with P3G, the Global Alliance for Genomics and Health, IRDiRC (International Rare Diseases Research Consortium), H3Africa and other organizations on the development of an International Code of Conduct for Genomic and Health-Related Data Sharing. A draft version is available for external review. Generic documents have been prepared covering areas of biobanking that are of major importance. SOPs have been finalized for blood withdrawal (SOPWP5001blood withdrawal), manual blood processing (SOPWP5002blood processing), shipping of biosamples (SOPWP5003shipping) and withdrawal, processing and storage of urine samples (SOPWP5004urine).gene-environment interaction, life-style, social circumstance, environment, phenotype, disease, biobank, socio-economic factor, data sharing, gene, clinicalSCR_003811(BioSHaRE, RRID:SCR_003811)University of Groningen; Groningen; Netherlands European Union FP7listed by: Consortia-pediaLast checked downnlx_158110
TRANSFoRm Data Integration ModelsResource, narrative resource, report, standard specification, data or information resourceA set of three models, which in conjunction with the semantic mediator enables the execution of queries formulated through the eligibility representation of the Clinical research information model (WT6.4). An ontology-driven mechanism was developed to enable linkage and integration of phenotypic and genotypic data from multiple distributed data sources. It makes use of the Clinical Data Integration Model (CDIM, WT6.5), the Data Source Model (DSM, WT6.6) and the CDIM-DSM mapping model (WT6.6). Queries formulated through the CDIM and vocabulary service (WT7.2) are translated to local queries by the mediator using the individual source instances of the DSM and CDIM-DSM models.clinical, modelSCR_003892(TRANSFoRm Data Integration Models, RRID:SCR_003892)TRANSFoRm uses: TRANSFoRm Clinical Data Integration Model, TRANSFoRm Clinical Research Information ModelLast checked downnlx_158223
TRACK TBI NetworkResource, narrative resource, knowledge environment, standard specification, data or information resourceNetwork evaluating consensus-based common data elements (CDE) for traumatic brain injury (TBI) and psychological health (TBI-CDE, while extensively phenotyping a cohort of TBI patients across the injury spectrum from concussion to coma. Institutions that participate in the TBI Network will be able to track the outcomes of patients through a 3, 6 and 12-month followup program and compare outcomes with other participating institutions. For the three acute care centers, patients were enrolled that presented to the emergency department within 24 hours of head injury and required computed tomography (CT). For the rehabilitation center, referrals from acute hospitals were enrolled. Patients were consented to participate in components: clinical profile; blood draws for measurement of proteomic and genomic markers; 3T MRI within 2 weeks; three-month Glasgow Outcome Scale-Extended (GOS-E); and six-month TBI-CDE Core outcome assessments. A web-enabled database, imaging repository, and biospecimen bank was developed using the TBI-CDE recommendations. A total of 605 patients were enrolled. Of these subjects, 88% had a GCS 13-15, 5% had a GCS 9-12, and 7% had a GCS of 8 or less. Three-month GOS-E''s were obtained for 78% of the patients. Comprehensive 6-month outcome measures, including PTSD assessment, are ongoing until September 2011. Blood specimens were collected from 450 patients. Initial CTs for 605 patients and 235 patients with 3T MRI studies were transferred to an imaging repository. The TRACK TBI Network will provide qualified institutions access to a web-based version of key forms in tracking TBI outcomes for Quality Improvement and institutional benchmarking.traumatic brain injury, concussion, coma, psychological health, common data element, head injury, mri, computed tomography, post-traumatic stress disorder, clinical, neuroimage, genomic, proteomic, outcome data, clinical data, marker, blood, glasgow outcome scale-extended, one mind tbi, one mind ptsd, image, image collection, benchmark, biomaterial supply resource, database, outcomeSCR_004723(TRACK TBI Network, RRID:SCR_004723)Traumatic brain injuryDefense and Veterans Brain Injury Center, Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury, NIDRR, NINDSlisted by: One Mind Biospecimen Bank ListingLast checked downnlx_143882
ISCA ConsortiumResource, database, international standard specification, standard specification, narrative resource, portal, community building portal, data or information resourceA rapidly growing group of clinical cytogenetics and molecular genetics laboratories committed to improving quality of patient care related to clinical genetic testing using new molecular cytogenetic technologies including array comparative genomic hybridization (aCGH) and quantitative SNP analysis by microarrays or bead chip technology. They improve clinical care by providing a large publicly available database and forum where clinicians and researchers can share knowledge to expedite the understanding of copy number variation (CNV) in an abnormal population. The ISCA database contains whole genome array data from a subset of the ISCA Consortium clinical diagnostic laboratories. Array analysis was carried out on individuals with phenotypes including intellectual disability, autism, and developmental delay. Efforts of the Consortium include: # Clinical Utility: The ISCA Consortium has made recommendations regarding the appropriate clinical indications for cytogenetic array testing (Miller et al. AJHG 2010, PMID: 20466091). Currently, discussions are focused on pediatric applications for children with unexplained developmental delay, intellectual disability, autism and other developmental disabilities. A separate committee has been developed to address appropriate cancer genetic applications ( # Evidence-based standards for cytogenomic array design: The Consortium will develop recommendations for standards for the design, resolution and content of cytogenomic arrays using an evidence-based process and an international panel of experts in clinical genetics, clinical laboratory genetics (cytogenetics and molecular genetics), genomics and bioinformatics. This design is intended to be platform and vendor-neutral (common denominator is genome sequence coordinates), and is a dynamic process with input from the broader genetics community and evidence-based review by the expert panel (which will evolve into a Standing Committee with international representation). # Public Database for clinical and research community: It is essential that publicly available databases be created and maintained for cytogenetic array data generated in clinical testing laboratories. The ISCA data will be held in dbGaP and dbVar at NCBI/NIH and curated by a committee of clinical genetics laboratory experts. The very high quality of copy number data (i.e., deletions and duplications) coming from clinical laboratories combined with expert curation will produce an invaluable resource to the clinical and research communities. # Standards for interpretation of cytogenetic array results: Using the ISCA Database, along with other genomic and genetics databases, the Consortium will develop recommendations for the interpretation and reporting of pathogenic vs. benign copy number changes as well as imbalances of unknown clinical significance.clinical, cytogenetics, molecular genetics, genetic testing, molecular cytogenetic technology, array comparative genomic hybridization, quantitative snp analysis, microarray, bead chip, genome, array, phenotype, copy number, deletion, duplication, copy number variationSCR_006168(ISCA Consortium, RRID:SCR_006168)Intellectual disability, Developmental delay, Etc., Autismrelated to: Database of Genomic Variants Archive, NCBI database of Genotypes and Phenotypes, UCSC Genome BrowserLast checked downnlx_151670
Endocrine SocietyResource, topical portal, training resource, narrative resource, portal, meeting resource, community building portal, data or information resourceFounded in 1916, The Endocrine Society is the world''s oldest, largest, and most active organization devoted to research on hormones and the clinical practice of endocrinology. The Society works to foster a greater understanding of endocrinology amongst the general public and practitioners of complementary medical disciplines and to promote the interests of all endocrinologists at the national scientific research and health policy levels of government. The Endocrine Society publishes four world-renowned journals and a monthly news magazine, holds scientific conferences, provides educational programs for physicians, issues clinical practice guidelines, promotes careers in endocrinology, and advocates for appropriate funding of scientific research in endocrinology and public policies that support the practice of clinical endocrinology. The Hormone Health Network, the Society''s public education affiliate, is a leading source of hormone-related health information for the public, physicians, allied health professionals and the media. The Endocrine Society is an international body with more than 15,000 members from over 100 countries. The Society''s diverse membership represents medicine, molecular and cellular biology, biochemistry, physiology, genetics, immunology, education, industry and allied health fields. Members of The Endocrine Society represent the full range of disciplines associated with endocrinologists: clinicians, researchers, educators, fellows and students, industry professionals and health professionals who are involved in the field of endocrinology. These professionals are dedicated to the research and treatment of the full range of endocrine disorders: diabetes, reproduction, infertility, osteoporosis, thyroid disease, obesity/lipids, growth hormone, pituitary tumors, and adrenal insufficiency.hormone, endocrinology, clinical, endocrinologistSCR_006449(Endocrine Society, RRID:SCR_006449)Endocrine disorder, Reproduction, Infertility, Osteoporosis, Thyroid disease, Obesity, Lipids, Growth hormone, Pituitary tumor, Adrenal insufficiency, Diabetesaffiliated with: Hormone Health NetworkLast checked downnlx_149400
Nex-StoCTResource, narrative resource, knowledge environment, standard specification, data or information resourceNational workgroup to define platform-independent approaches for establishing technical process elements of a quality management system (QMS) to assure the analytical validity and compliance of next-generation sequencing (NGS) tests with existing regulatory and professional quality standards. The workgroup identified and addressed gaps in quality practices that could compromise the quality of both clinical laboratory services and translational efforts needed to advance the implementation and utility of NGS in clinical settings. The workgroup was composed of experts with knowledge of and experience with NGS and included clinical laboratory directors, clinicians, platform and software developers and informaticians, as well as individuals actively engaged in NGS guideline development from accreditation bodies and professional organizations. Representatives from US government agencies also participated. These guidelines address four topics that are components of quality management in a clinical environment: (i) test validation, (ii) quality control (QC) procedures to assure and maintain accurate test results, (iii) the independent assessment of test performance through proficiency testing (PT) or alternative approaches and (iv) reference materials (RMs). Discussions were limited to the analytic and informatics processes required for accurate variant calling. The workgroup did not address how variants are prioritized, interpreted or sequencing, clinical, testing, test resultSCR_006777(Nex-StoCT, RRID:SCR_006777)Centers for Disease Control and Prevention listed by: OMICtoolsPMID:23138292Last checked downOMICS_01787
aneurISTResource, topical portal, production service resource, analysis service resource, data analysis service, standard specification, narrative resource, service resource, portal, knowledge environment, data or information resourceAn IT infrastructure for the management, integration and processing of data associated with the diagnosis and treatment of cerebral aneurysm and subarachnoid hemorrhage. This new paradigm to understand and manage cerebral aneurysms, provides an integrated decision support system to assess the risk of aneurysm rupture in patients and to optimize their treatments. aneurIST benefits patients with better diagnostics, prevention and treatment because it combines efforts of clinicians and industry. Through research clinicians gain a greater insight in aneurysm understanding, while industry will be dragged by these achievements to develop more suitable medical devices to treat the disease. This infrastructure : * Facilitate clinicians the diagnosis and study of the disease, as a result of providing a seamless access to patient data using data fusion and processing of complex information spanning from the molecular to the personal level. * Provide a better planning and personalization of minimally invasive interventional procedures for patients, after linking modern diagnostic imaging to computational tools. * Collaborate in the development, extension and exploitation of standards and protocols at all project stages. * Share biomedical knowledge providing access to a set of software tools and platforms such as aneuLink, aneuFuse, aneuRisk, aneuEndo, aneuCompute and aneuInfo. * Create awareness through scientific dissemination and collaboration. * Explore the business opportunities directly arising from aneurIST. It intends to provide an integrated decision support system to assess the risk of aneurysm rupture in patients and to optimize their treatments. Software: * aneuLink will create an IT environment with the goal of establishing a link between genomics and disease. * aneuFuse will fuse diagnostic, modelling and simulation data into a coherent representation of the patient''s condition. * aneuRisk will provide clinicians with a tool to facilitate the personalized risk assessment and guidelines establishment to treat patients. * aneuEndo will develop computational tools to optimize and customize the design of endovascular devices. * aneuInfo will enable access to clinical and epidemiological data distributed in public and project-specific protected databases. * aneuCompute will provide aneurIST with distributed computing capabilities ensuring secure data transport.gene, genetic, adult, cerebral aneurysm, cerebral brain hemorrhage, cerebral hemorrhage, cerebral parenchymal hemorrhage, cerebral hemorrhage, clinical, genomic, human, intracerebral hemorrhage, intracranial aneurysm, subarachnoid hemorrhage, risk, aneurysm rupture, patient, treatment, infrastructure, platform, genomics, disease, personalized risk assessment, bioinformatics, clinical, data management, data integration, data processing, software tool, cerebrumSCR_007427(aneurIST, RRID:SCR_007427)Pompeu Fabra University; Barcelona; Spain Cerebral aneurysm, Subarachnoid hemorrhage, AgingEuropean Union, Sixth FPPriority 2 of the Information Society Technologies ISTLast checked downnif-0000-00538
AIDSinfo Drug DatabaseResource, narrative resource, data or information resource, training material, databaseThe AIDSinfo Drug Database provides fact sheets on HIV/AIDS related drugs. The fact sheets describe the drug''s use, pharmacology, side effects, and other information. The database includes: -Approved and investigational HIV/AIDS related drugs -Three versions of each fact sheet: patient, health professional, and Spanish. AIDSinfo is a 100% federally funded U.S. Department of Health and Human Services (DHHS) project that offers the latest federally approved information on HIV/AIDS clinical research, treatment and prevention, and medical practice guidelines for people living with HIV/AIDS, their families and friends, health care providers, scientists, and researchers. Sponsors: -National Institutes of Health (NIH) Office of AIDS Research National Institute of Allergy and Infectious Diseases (NIAID) National Library of Medicine (NLM) -Health Resources and Services Administration (HRSA) -Centers for Disease Control and Prevention (CDC) -Centers for Medicare and Medicaid Services (CMS)drug, drug and food interactions, fact sheet, fda-approved, aids, clinical, contraindications, hiv, human, information, investigational, manufacturer information, pharmacology, prevention, research, side effect, side effects, treatmentSCR_012899(AIDSinfo Drug Database, RRID:SCR_012899)National Institutes of Health Last checked downnif-0000-21014
College on Problems of Drug DependenceResource, topical portal, training resource, journal article, narrative resource, service resource, training material, meeting resource, portal, training service resource, data or information resourceThe College on Problems of Drug Dependence (CPDD) is an interdisciplinary research society whose members address problems of drug dependence in the broadest range of scientific disciplines, including chemistry, basic biology, pharmacology, behavioral science, clinical research, sociology, psychology, anthropology, and history. CPDD serves as an interface among governmental, industrial and academic communities maintaining liaisons with regulatory and research agencies as well as educational, treatment, and prevention facilities in the drug abuse field. It also functions as a collaborating center of the World Health Organization. The Annual Scientific Meeting: Since 1938, a major focus of the CPDD's activities has been its sponsorship of an annual scientific meeting. This conference serves as a forum bringing together basic scientists and clinical investigators from industry, academia, and government. Representatives of regulatory agencies, as well as scientists and professionals in a number of diverse disciplines interested in the biochemical, behavioral, and public health aspects of drug dependence participate. Special Conferences: Periodically, the College sponsors conferences focused on timely topics of interest to researchers, government, industry, and the public. In recent years, CPDD has organized meetings on Abuse Liability Assessment of CNS Drugs; Drug Formulation and Abuse Liability; Pre-Clinical Abuse Liability Testing; Women and Smoking: Understanding Socioeconomic Influences; and Risk Management and Post-Marketing Surveillance for CNS-Acting Drugs. Consultation Activities: The CPDD provides consulting expertise in the area of epidemiology, treatment, prevention, and all the basic and clinical sciences related to drug dependence, drug abuse, and their behavioral and medical consequences. Sponsorship of Drug and Alcohol Dependence: The CPDD sponsors the journal Drug and Alcohol Dependence, published by Elsevier. A principal goal of the journal is to provide a source of quality, timely reports of scientific advances in substance abuse research. The journal is international in scope and interdisciplinary in coverage. The CPDD invites contributors. Donations Tax-deductible donations can be made to CPDD to support the Annual Scientific Meeting, testing facilities, drug assessment activities and Awards for Excellence.drug, drug abuse, drug dependence, educational opportunity, epidemiology, fact sheets, fellowship, funding, alcohol, animal, anthropology, basic, basic biology, behavioral, behavioral science, biochemical, chemistry, clinical, clinical research, consulting, history, job, medical consequences, opioids, pharmacology, pharmacotherapy, prevention, psychology, public health, research, society, sociology, substance abuse, tobacco, treatmentSCR_002618(College on Problems of Drug Dependence, RRID:SCR_002618)Virginia Commonwealth University; Virginia; USA Last checked upnif-0000-21909
Coalition For Accelerating Standards and TherapiesResource, organization portal, consortium, standard specification, narrative resource, portal, data or information resourceConsortium establishing data standards, tools and methods for conducting research in therapeutic areas important to public health including: Alzheimer's disease, Parkinson's disease, multiple sclerosis, polycystic kidney disease, and tuberculosis. For each therapeutic area, CFAST aims to create the following products: * User/implementation guide * Core data elements with definitions, data types, Biomedical Research Integrated Domain Group (BRIDG)/Study Data Tabulation Model (SDTM) mappings * SDTM domains and examples * Controlled terminology/allowable value sets; along with definitions and data types, all efforts should be made to identify existing work that can be adopted or adapted to meet the requirements before new controlled terminologies or element definitions are developed * Standard CDASH case report forms (CRFs) and SDTM annotations * Examples of Standard for Exchange of Nonclinical Data (SEND) non-clinical data, where appropriate These tools aim to provide a defined and consistent way to collect, store, and submit clinical trial data, allowing researchers to combine and evaluate data from multiple studies using a common approach. In addition to accelerating basic research, these standards also aim to enhance the design of clinical trials and the evaluation of new medical products, such as clinical trial simulation models and methods to evaluate treatment endpoints. All of the tools created by CFAST aim to enable researchers to guide the organization, structure and format of standard clinical trial tabulation datasheets that are submitted to a regulatory authority. Collaborators include the U.S. Food and Drug Administration (FDA), TransCelerate BioPharma and the National Cancer Institute Enterprise Vocabulary Services (NCI-EVS), with participation and input from many Critical Path Institute (C-Path) and Clinical Data Interchange Standards Consortium (CDISC) members as well as other organizations. Any clinical data standards produced under this partnership will be created under the CDISC standards development process, and those standards will then be published openly on the CDISC website as a global CDISC standard.consortium, drug, clinical trial, data element, data sharing, clinical, virologySCR_000206(Coalition For Accelerating Standards and Therapies, RRID:SCR_000206)Critical Path Institute; Arizona; USA FDAlisted by: Consortia-pediaLast checked upnlx_157879
Washington University Knight Alzheimers Disease Research CenterResource, disease-related portal, topical portal, bibliography, assessment test provider, brain bank, training resource, biomaterial supply resource, tissue bank, narrative resource, service resource, portal, storage service resource, training material, material storage repository, material resource, postdoctoral program resource, data or information resourceResearch center which facilitates advanced research on the clinical, genetic, neuropathological, neuroanatomical, biomedical, psychosocial, and neuropsychological aspects of Alzheimer's disease, as well as other related brain disorders. This center is supported by the National Institute on Aging and, more specifically, is a research arm of the Memory and Aging Project.genetic, alzheimers disease, biomedical, brain, clinical, cure, dementia, development, disease, neuroanatomical, neurodegenerative disease, neuropathological, neuropsychological, research, senile, treatment, agingSCR_000210(Washington University Knight Alzheimers Disease Research Center, RRID:SCR_000210)Washington University in St. Louis; Missouri; USA Alzheimer's disease, Dementia, AgingNIALast checked upnif-0000-11285, nlx_144153, SCR_008779
Clinical Data Interchange Standards ConsortiumResource, organization portal, consortium, standard specification, narrative resource, portal, data or information resourceA global, open, multidisciplinary, non-profit organization that has established standards to support the acquisition, exchange, submission and archive of clinical research data and metadata. Its mission is to develop and support global, platform-independent data standards that enable information system interoperability to improve medical research and related areas of healthcare. CDISC standards are vendor-neutral, platform-independent and freely available via the CDISC website.clinical, data sharing, interoperability, medical, healthcareSCR_000219(Clinical Data Interchange Standards Consortium, RRID:SCR_000219)related to: Critical Path to TB Drug Regimens, eTRIKS, used by: TRANSFoRm Clinical Research Information ModelLast checked upnlx_157914
Health Level Seven InternationalResource, organization portal, international standard specification, standard specification, narrative resource, portal, data or information resourceANSI-accredited standards developing organization providing a comprehensive framework and related standards for the exchange, integration, sharing, and retrieval of electronic health information that supports clinical practice and the management, delivery and evaluation of health services. HL7's 2,300+ members include approximately 500 corporate members who represent more than 90% of the information systems vendors serving healthcare. HL7 provides standards for interoperability that improve care delivery, optimize workflow, reduce ambiguity and enhance knowledge transfer among all of their stakeholders, including healthcare providers, government agencies, the vendor community, fellow SDOs and care, interoperability, health, health service, clinical, managementSCR_000466(Health Level Seven International, RRID:SCR_000466)Last checked upnlx_157307
Psychology CornerResource, blog, narrative resource, data or information resourceA blog by a Romanian clinical psychologist and psychotherapist Lucia Grosaru. Major categories include: General, lifestyle, news, pensees, psychologists, psychotherapy, self-help and video. Lucia Grosaru is the President and a Founding Member of the Romanian Institute Sic Cogito, Founding Member for The Romanian Center of Psychology and a Founding Editor of The Romanian Journal of Psychology, Psychotherapy and Neuroscience. Lucia is an integrative psychotherapist, clinical psychologist and a Certified Rorschach Inkblot Test Specialist (Method: Scuola Romana Rorschach, Italy). She has graduated the Psychology and Educational Science Faculty at the University of Bucharest in 2008 and the Cognitive Psychodiagnosis and Counseling Master's Programme in 2010.psychology, clinical, psychologist, integrative psychotherapist, rorschach psychodiagnosis, psychotherapy, neuroscience, researchSCR_000630(Psychology Corner, RRID:SCR_000630)used by: NIF Data Federation, Integrated BlogsLast checked upnlx_151806
BioPortfolioResource, blog, database, narrative resource, portal, data or information resource, job resourceBioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to source core information on specific bio-related topics, to collate relevant data associated with each topic and to point the user to relevant knowledge resources. We publish up to the minute news (see biotechnology news categories) and regularly update content across our information databases. BioPortfolio promotes and sells market research and management reports from 30+ publishers. In addition our unique corporate database lists 40,000+ companies and organizations. BioPortfolio aims to bring together high quality information about marketed drugs - medication and relevant clinical trials, research papers and recent news from PubMed,, and DailyMed. Additionally, resources include biotech, pharma and medical job listings. When the BioPortfolio site was launched in February 1997 the company aimed to provide a global free-to-use resource with defined aims and mission statement: to meet the increasing demand of consumers, scientists, investors, commerce and government for timely, accurate and commercially useful information and intelligence on biotechnology companies, technologies and products world-wide. Driven by the success of the site we have made major investments and improvements to enhance our content and to apply the latest web technologies to improve functionality and site utility. We believe this unique depth and breadth of content is supporting individuals, organizations and policy-makers to become more aware of the role of biotechnology on the global economy. With 97,000 users visiting the site more than once per month we are confident that we are providing information our users need. We hope you the users find the site of value for both personal and professional reasons. Please enjoy this free resource and email your comments!news, information, knowledge, life science, biotechnology, pubmed, corporate, clinical trial, drug, career, pharmaceutical, healthcare, medicine, clinical, industrySCR_005230(BioPortfolio, RRID:SCR_005230)used by: NIF Data Federation, Integrated BlogsLast checked upnlx_144235
  1. RRID Portal Resources

    Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.

  2. Navigation

    You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.

  3. Logging in and Registering

    If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.

  4. Searching

    Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:

    1. Use quotes around phrases you want to match exactly
    2. You can manually AND and OR terms to change how we search between words
    3. You can add "-" to terms to make sure no results return with that term in them (ex. Cerebellum -CA1)
    4. You can add "+" to terms to require they be in the data
    5. Using autocomplete specifies which branch of our semantics you with to search and can help refine your search
  5. Collections

    If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.

  6. Facets

    Here are the facets that you can filter the data by.

  7. Further Questions

    If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.